Oxford Biomedica plc (LON:OXB - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is GBX 687.
Several research firms recently issued reports on OXB. Deutsche Bank Aktiengesellschaft raised their price target on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a "buy" rating in a report on Friday, January 9th. Stifel Nicolaus reaffirmed a "buy" rating and set a GBX 950 price target on shares of Oxford Biomedica in a research note on Wednesday, March 11th. Finally, Jefferies Financial Group assumed coverage on shares of Oxford Biomedica in a research report on Monday, March 23rd. They issued a "buy" rating and a GBX 827 price objective on the stock.
Get Our Latest Stock Analysis on Oxford Biomedica
Oxford Biomedica Stock Performance
Oxford Biomedica stock opened at GBX 560 on Friday. The company has a debt-to-equity ratio of 116.74, a current ratio of 2.20 and a quick ratio of 1.67. The stock has a fifty day moving average price of GBX 702.33 and a two-hundred day moving average price of GBX 663.73. Oxford Biomedica has a 52-week low of GBX 232.50 and a 52-week high of GBX 952. The firm has a market capitalization of £676.88 million, a P/E ratio of -15.46 and a beta of 1.04.
Oxford Biomedica (LON:OXB - Get Free Report) last issued its earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) EPS for the quarter. Oxford Biomedica had a negative net margin of 17.85% and a negative return on equity of 48.56%. As a group, analysts anticipate that Oxford Biomedica will post -31.0799998 EPS for the current fiscal year.
Oxford Biomedica Company Profile
(
Get Free Report)
Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
